2月25日，丰倍生物跌3.55%，成交额1.74亿元。两融数据显示，当日丰倍生物获融资买入额1721.77万 元，融资偿还3269.51万元，融资净买入-1547.74万元。截至2月25日，丰倍生物融资融券余额合计 7981.37万元。 融资方面，丰倍生物当日融资买入1721.77万元。当前融资余额7981.37万元，占流通市值的4.77%。 融券方面，丰倍生物2月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，苏州丰倍生物科技股份有限公司位于江苏省常州市金坛区兴河东路19号，成立日期2014年7 月25日，上市日期2025年11月5日，公司主营业务涉及以废弃油脂资源综合利用业务为主,油脂化学品业 务为辅。主营业务收入构成为：废弃资源综合利用业务91.18%，其中:生物基材料79.60%，其中:生物燃 料11.58%，油脂化学品8.66%，其他(补充)0.16%。 截至12月10日，丰倍生物股东户数2.76万，较上期减少50.19%；人均流通股1123股，较上期增加 100.77%。2025年1月-9月，丰倍生物实现营业 ...

Group 1 - The core viewpoint of the news is that Fengbei Bio experienced a decline in stock price and trading volume, with significant net financing outflows on February 12, indicating potential investor concerns [1] - On February 12, Fengbei Bio's stock price fell by 3.03%, with a trading volume of 199 million yuan. The net financing buy was -6.46 million yuan, with a total financing balance of 97.52 million yuan, accounting for 5.87% of the circulating market value [1] - The company specializes in the comprehensive utilization of waste oil resources, with its main business revenue composition being 91.18% from waste resource utilization, including 79.60% from bio-based materials and 11.58% from biofuels [1] Group 2 - As of December 10, the number of shareholders for Fengbei Bio was 27,600, a decrease of 50.19% from the previous period, while the average circulating shares per person increased by 100.77% [2] - For the period from January to September 2025, Fengbei Bio achieved an operating income of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to the parent company of 117 million yuan, up 35.32% year-on-year [2]

从资金流向上来看，当日生物柴油板块主力资金净流出5550.39万元，游资资金净流入4610.1万元，散户 资金净流入940.29万元。生物柴油板块个股资金流向见下表： 证券之星消息，2月12日生物柴油板块较上一交易日下跌0.82%，丰倍生物领跌。当日上证指数报收于 4134.02，上涨0.05%。深证成指报收于14283.0，上涨0.86%。生物柴油板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core point of the news is that Fengbei Biotechnology's stock has experienced a decline of 2.54%, with a total market value of 7.937 billion yuan and a cumulative drop of 6.73% over three consecutive days [1] - Fengbei Biotechnology, established on July 25, 2014, focuses on the comprehensive utilization of waste oil resources, with 91.18% of its revenue coming from this segment, including 79.60% from bio-based materials and 11.58% from biofuels [1] - The company's stock price is currently at 55.31 yuan per share, with a trading volume of 189 million yuan and a turnover rate of 10.80% [1] Group 2 - E Fund's fund holds a small position in Fengbei Biotechnology, with 88 shares representing 0.0002% of the circulating shares, ranking as the fourth largest holding [2] - The fund has incurred a floating loss of approximately 126.72 yuan today and a total floating loss of 351.12 yuan during the three-day decline [2] - E Fund's fund has a total asset size of 5.93 billion yuan, with a year-to-date return of 15.3% and a cumulative return of 20.92% since inception [2]

Core Viewpoint - The biodiesel sector experienced a decline of 1.1% on February 10, with Fengbei Bio leading the drop. The Shanghai Composite Index rose by 0.13%, while the Shenzhen Component Index increased by 0.02% [1]. Group 1: Market Performance - The closing price of Fengbei Bio was 56.75, reflecting a decrease of 3.21% [1]. - The biodiesel sector saw a net outflow of 56.84 million yuan from main funds, while retail investors contributed a net inflow of 46.01 million yuan [1]. - The trading volume for the biodiesel sector was significant, with stocks like Zhongliang Technology and Haixin Energy showing notable trading activity [1]. Group 2: Individual Stock Analysis - Zhongliang Technology closed at 6.43, down by 0.77%, with a trading volume of 217,100 shares [1]. - Fengbei Bio had a net outflow of 8.37 million yuan from main funds, while retail investors contributed a net inflow of 5.62 million yuan [2]. - The stock of Zhuoyue New Energy closed at 76.28, down by 1.56%, with a significant net outflow of 19.20 million yuan from main funds [2].

Core Viewpoint - Fengbei Bio (603334) has experienced significant stock price fluctuations, with a recent increase of 25.93% to 59.3 yuan as of February 6, 2026, indicating strong market interest and trading activity [1][8]. Trading Information Summary - Fengbei Bio was listed on the "Dragon and Tiger List" for two consecutive days due to a daily turnover rate reaching 20% on February 5 and 6, 2026, marking its second appearance in the last five trading days [2][5]. - The stock also saw a cumulative price deviation exceeding 20% over two consecutive trading days, indicating abnormal trading activity [8]. Company Development and Products - Established in 2014, Fengbei Bio focuses on the comprehensive utilization of waste oil resources and has entered a rapid growth phase since 2018, emphasizing bio-based materials and biofuels [3]. - The main business includes waste oil resource utilization, with products such as bio-based materials (e.g., pesticide and fertilizer additives) and biofuels (e.g., biodiesel) [3][4]. - In the first half of 2025, the company produced 47,706.75 tons of biodiesel and 142,814.10 tons of industrial-grade mixed oil [4][5]. Market and Regulatory Environment - The company holds ISCC certification, allowing it to enter the EU market, which has stringent requirements for biofuel products [6]. - The revised Renewable Energy Directive (RED) aims to increase the EU's renewable energy target to at least 42.5% by 2030, impacting the biofuel market [6]. Client Relationships - Fengbei Bio collaborates with major global commodity traders and end customers, including TRFIGUR, GLENCORE, and SHELL, for its biodiesel sales [6]. - The company has established partnerships with key SF manufacturers for the sale of industrial-grade mixed oil [6]. Raw Material Sourcing - Waste oil is sourced from food processing, chemical companies, and kitchen waste treatment enterprises, with a nationwide supply network and efforts to expand overseas [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 苏州丰倍生物科技股份有限公司（以下简称"公司"）股票于2026年2月4日、2月5日连续2个交易日内 日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 ● 经公司自查，并向公司控股股东、实际控制人发问询函，截至本公告披露日，除公司已披露的事项 外，不存在其他应披露而未披露的重大信息。 ● 公司股价短期波动幅度较大，敬请广大投资者理性决策，注意投资风险。 一、股票交易异常波动的具体情况 公司股票交易于2026年2月4日、2月5日连续2个交易日内日收盘价格涨幅偏离值累计超过20%，根据 《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，公司目前生产经营活动一切正常，市场环境、行业政策没有发生重大调整、生产成本和销 售等情况没有出现大幅波动、内部生产经营秩序正常。 （二）重大事项情况 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603334 证券简称：丰倍生物 公告编号：2026-001 苏州丰倍生物科技股份有限公司股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 苏州丰倍生物科技股份有限公司（以下简称"公司"）股票于2026年2月4日、2月5日连续2个交易日内 日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 ● 经公司自查，并向公司控股股东、实际控制人发问询函，截至本公告披露日，除公司已披露的事项 外，不存在其他应披露而未披露的重大信息。 ● 公司股价短期波动幅度较大，敬请广大投资者理性决策，注意投资风险。 一、股票交易异常波动的具体情况 公司股票交易于2026年2月4日、2月5日连续2个交易日内日收盘价格涨幅偏离值累计超过20%，根据 《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，公司目前生产经营活动一切正常 ...

（编辑 袁冠琳） 证券日报网讯 2月5日，丰倍生物发布公告称，公司股票交易于2026年2月4日、2026年2月5日连续2个交 易日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票 交易异常波动情形。本公司董事会确认，除公司已披露的信息外，本公司没有任何根据《上海证券交易 所股票上市规则》等有关规定应披露而未披露的事项或与该等事项有关的筹划、商谈、意向、协议等， 董事会也未获悉根据《上海证券交易所股票上市规则》等有关规定应披露而未披露的、对本公司股票及 其衍生品种交易价格可能产生较大影响的信息；公司前期披露的信息不存在需要更正、补充之处。 ...

证券代码：603334 证券简称：丰倍生物 公告编号：2026-001 苏州丰倍生物科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 苏州丰倍生物科技股份有限公司（以下简称"公司"）股票于 2026 年 2 月 4 日、2 月 5 日连续 2 个交易日内日收盘价格涨幅偏离值累计超过 20%，根据 《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 经公司自查，并向公司控股股东、实际控制人发问询函，截至本公告披 露日，除公司已披露的事项外，不存在其他应披露而未披露的重大信息。 公司股价短期波动幅度较大，敬请广大投资者理性决策，注意投资风险。 一、股票交易异常波动的具体情况 公司股票交易于 2026 年 2 月 4 日、2 月 5 日连续 2 个交易日内日收盘价格 涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于 股票交易异常波动情形。 （三）媒体报道、市场传闻、热点概念情况 经公司自查，公司未发现对公司股票交易价格可能产生较大影响的媒体 ...